T1	Participants 75 81	autism
T2	Participants 604 696	all children with assays using C-terminal antibody but not with an N-terminal antibody assay
T3	Participants 711 730	70% of the children
T4	Participants 799 814	smaller subsets
T5	Participants 909 933	best clinical responders
T6	Participants 1165 1207	those children who received NTX before PLC
T7	Participants 1254 1354	subgroup of autistic children, who may be identified by the presence of certain plasma abnormalities
T8	Participants 1445 1516	those related to the pro-opiomelanocortin system, and autistic symptoms
